TCGA-55-8512-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 41
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.330
- BILE_ACID_METABOLISM+0.310
- MYOGENESIS+0.270
- HEDGEHOG_SIGNALING+0.260
- ESTROGEN_RESPONSE_EARLY+0.240
- TNFA_SIGNALING_VIA_NFKB+0.240
- XENOBIOTIC_METABOLISM+0.170
- UV_RESPONSE_DN+0.140
- COAGULATION+0.100
- ESTROGEN_RESPONSE_LATE+0.100
Top 10 suppressed
- E2F_TARGETS-0.700
- MYC_TARGETS_V1-0.700
- G2M_CHECKPOINT-0.640
- MYC_TARGETS_V2-0.630
- MTORC1_SIGNALING-0.540
- OXIDATIVE_PHOSPHORYLATION-0.530
- UNFOLDED_PROTEIN_RESPONSE-0.500
- PROTEIN_SECRETION-0.460
- ALLOGRAFT_REJECTION-0.410
- DNA_REPAIR-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-00444 | — | cohortA1 | 0.926 |
| 2 | BS_AKRHBPNZ | Ganglioglioma | — | 0.900 |
| 3 | TCGA-55-8616-01A-11R-2403-07 | — | cohortA1 | 0.897 |
| 4 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.896 |
| 5 | BS_V7BJM89K | low-grade glioma | — | 0.895 |
| 6 | MDT-AP-1121 | Med | Medulloblastoma | 0.892 |
| 7 | SRR1313116 | — | A | 0.888 |
| 8 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.885 |
| 9 | MNG4 | — | — | 0.882 |
| 10 | BS_QV51J756 | Ganglioglioma | — | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |